Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) regularly issues news on its medicines, clinical programs and corporate developments across multiple therapeutic areas. As a biotechnology company focused on serious diseases, Regeneron’s announcements often cover advances in eye care, allergic and inflammatory diseases, oncology, hematology, cardiovascular disease, infectious disease and rare conditions.
News about Regeneron frequently highlights regulatory milestones for its marketed products. Recent examples include approvals for Dupixent (dupilumab) in additional indications and age groups, such as chronic spontaneous urticaria in the European Union and bronchial asthma in children in Japan, as well as expanded indications and dosing flexibility for EYLEA HD (aflibercept) Injection 8 mg in retinal diseases. The company also reports on new approvals for Libtayo (cemiplimab), including adjuvant treatment of cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation in the European Union.
Investors and healthcare professionals can expect updates on Regeneron’s oncology and hematology pipeline, including data from trials of Lynozyfic (linvoseltamab) in multiple myeloma and odronextamab in B‑cell non‑Hodgkin lymphomas, as well as programs in paroxysmal nocturnal hemoglobinuria and severe aplastic anemia. Regeneron often presents such data at major medical meetings, and issues press releases summarizing efficacy and safety results.
Corporate and R&D collaboration news is another recurring theme. The company has announced partnerships such as its global collaboration with Tessera Therapeutics on TSRA‑196, an investigational in vivo gene editing therapy for alpha‑1 antitrypsin deficiency, and provides updates on its factor XI antibody program for anticoagulation. Regeneron also communicates scheduling of quarterly and annual financial results webcasts and investor events, including its ‘Regeneron Roundtable’ series.
This news page aggregates these types of updates so readers can follow product approvals, late-stage trial readouts, scientific presentations, strategic collaborations and financial reporting dates related to REGN. For ongoing research and investment analysis, checking this feed regularly can provide timely insight into Regeneron’s progress across its broad portfolio.
Regeneron (NASDAQ: REGN) will report first quarter 2026 financial and operating results on Wednesday, April 29, 2026 before U.S. markets open. The company will host a conference call and simultaneous webcast at 8:30 AM ET that day.
According to the company, the webcast will be available on its Investors and Media page and telephone participation requires advance registration; a replay and transcript will be archived on the company website for at least 30 days.
Regeneron (NASDAQ: REGN) and Sanofi announced that Japan's MHLW approved Dupixent (dupilumab) for adults with moderate-to-severe bullous pemphigoid (BP), the first targeted therapy for BP in Japan and Dupixent's seventh Japanese indication.
Approval was based on the LIBERTY-BP-ADEPT Phase 2/3 trial where Dupixent plus corticosteroid taper showed sustained remission at Week 36 in 18% vs 4% with placebo (p=0.0250). Treatment-related adverse events occurred in 26% of Dupixent patients versus 15% for placebo; conjunctivitis was reported in 4% of Dupixent patients.
Regeneron (NASDAQ: REGN) and Society for Science honored 40 finalists in the 2026 Regeneron Science Talent Search, awarding more than $1.8 million to finalists and a $250,000 top prize to Connor Hill. Regeneron pledged an additional $150 million to extend title sponsorship through 2036, bringing total support for Regeneron STEM programs to over $300 million from 2017 to 2036.
Forty finalists received awards for original research across computational math, neuroscience, and blood cancer models; the competition recognized a total of $3.1 million in awards and named Colin Jie Chu the Seaborg Award winner.
Regeneron (NASDAQ: REGN) reported positive Phase 3 topline results from Hansoh's 48-week trial of olatorepatide in Chinese adults with obesity or overweight. The randomized, double-blind trial (N=604) met co-primary endpoints with up to 19% mean weight loss at week 48 and up to 97% achieving ≥5% weight loss.
The program showed favorable gastrointestinal tolerability (nausea 10%, vomiting <5%). Regeneron plans to initiate a global registrational Phase 3 program later in 2026; detailed data will be presented at a medical meeting. Safety and efficacy remain unevaluated by regulators.
Regeneron (NASDAQ: REGN) will webcast management participation at the Barclays 28th Annual Global Healthcare Conference at 9:00 a.m. ET on Tuesday, March 10, 2026. The session is available from the company’s Investors & Media page, with a replay and transcript archived for at least 30 days.
Regeneron and Sanofi (NASDAQ: REGN) announced a positive CHMP opinion recommending EU approval of Dupixent (dupilumab) to treat chronic spontaneous urticaria (CSU) in children aged 2–11 with inadequate response to H1 antihistamines and naive to anti-IgE therapy.
The opinion is supported by LIBERTY-CUPID Phase 3 data; a final EU decision is expected in coming months and a U.S. FDA decision is expected by April 2026.
Regeneron (NASDAQ: REGN) renews title sponsorship of the Regeneron Science Talent Search (STS) through 2036, pledging an additional $150 million and bringing its 20-year STS investment to $250 million. Combined STS and ISEF support totals more than $300 million from 2017–2036.
The renewal continues funding for STEM outreach, cites a 49% increase in STS entries since 2017, and notes engagement of over 20,000 students and recognition of 3,000 Regeneron scholars.
Regeneron (NASDAQ: REGN) and Sanofi announced FDA approval of Dupixent (dupilumab) on Feb 24, 2026 for treating allergic fungal rhinosinusitis (AFRS) in adults and children aged 6+ with a history of sino-nasal surgery.
Approval was based on a Phase 3 trial showing marked reductions in sinus opacification, nasal symptoms, polyp size, and a 92% reduction in risk of systemic corticosteroid use or surgery over 52 weeks.
Regeneron (NASDAQ: REGN) announced the FDA has accepted the Biologics License Application for garetosmab for adults with fibrodysplasia ossificans progressiva (FOP) and granted Priority Review with a target action date in August 2026.
The BLA is supported by positive Phase 3 OPTIMA results showing large reductions in new heterotopic bone lesions and volume versus placebo, and a safety profile with common adverse reactions including epistaxis and increased hair growth.
Regeneron (NASDAQ: REGN) will webcast management presentations at two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 9:10 a.m. ET and Leerink Partners 2026 Global Healthcare Conference on March 11, 2026 at 10:40 a.m. ET.
According to the company, sessions are accessible via its Investors & Media page, with replays and transcripts archived on the website for at least 30 days.